Results for tumorbyrde translation from Danish to English

tumorbyrde
tumour burden

lever- tumorbyrde
liver tumour burden

forbehandling af patienter med stor tumorbyrde
pre-phase treatment for patients with high tumour burden

tumorbyrde ved baseline var kun tilgængelig i studie bo22334.
baseline tumour load was available only in trial bo22334.

patienter med en stor tumorbyrde bør anses for at have en øget risiko for tls.
patients with a high tumour burden should be considered to be at greater risk for tls.

det er patienter med stor tumorbyrde inden behandlingen, som har risiko for at få tls og tfr.
the patients at risk of tls and tfr are those with high tumour burden prior to treatment.

patienter med risiko for tumorlysesyndrom er dem, der allerede har en høj tumorbyrde forud for behandlingen.
the patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment.

det er de patienter, der har stor tumorbyrde inden behandlingen, som har risiko for at få tumorlysesyndrom.
the patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment.

de patienter, der har risiko for tumorlysesyndrom, er dem, der har en stor tumorbyrde forud for behandlingen.
patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment.

behandling af follikulær lymfom med stor tumorbyrde i kombination med passende induktionskemoterapi, såsom chop-lignende regimer.
treatment of high tumour burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a chop-like regimen.

i lenalidomidarmen seponerede 11/81 (14 %) patienter med stor tumorbyrde behandlingen i løbet af behandlingscyklus 1 vs.
during treatment cycle 1, 11/81 (14%) patients with high tumour burden were withdrawn from therapy in the lenalidomide arm vs.

patienter med tydeligt øget tumorbyrde inden gennemførelse af induktionsbehandlingen, fik forlænget induktionsbehandling, hvis det blev tolereret og hvis de havde en passende performance status.
patients with apparent tumour burden increase before completion of the induction period were continued on induction therapy as tolerated if they had adequate performance status.

selvom der korrigeredes for cd- 19 positive celletal og størrelsen af tumorbyrde, var der stadig store interindividuelle variationer i cl2 v1 varierede i forhold til kroppens overfladeareal og chop kemoterapi.
v1 varied by body surface area (bsa) and chop therapy.

forebyggelse af tumorlysesyndrom hos patienter med en høj tumorbyrde skal profylaktisk behandling med allopurinol til kontrol af serumniveauer for urinsyre, sammen med adækvat eller forhøjet hydrering, påbegyndes 24 timer før starten af kemoterapi.
prevention of tumour lysis syndrome in patients with a high tumour burden, prophylactic allopurinol therapy to control serum levels of uric acid, together with adequate or increased hydration, should be commenced 24 hours before the start of chemotherapy.

den primære årsag til, at patienter med stor tumorbyrde seponerede lenalidomid i løbet af behandlingscyklus 1, var bivirkninger, 7/11 (64 %).
the main reason for treatment withdrawal for patients with high tumour burden during treatment cycle 1 in the lenalidomide arm was adverse events, 7/11 (64%).

studie mcl-002: i lenalidomidarmen seponerede 11/81 (14 %) patienter med stor tumorbyrde behandlingen i løbet af behandlingscyklus 1 vs.
in study mcl-002, during treatment cycle 1, 11/81 (14%) patients with high tumour burden were withdrawn from therapy in the lenalidomide arm vs.

baseline af antallet af cd-19 positive celletal og størrelsen af målte tumorbyrde, forklarer noget af variationen i cl2 af rituximab fra 161 patienter, som fik 375 mg/m2 ugentlig i 4 uger som iv infusion.
baseline cd19-positive cell counts and size of measurable tumor lesions contributed to some of the variability in cl2 of rituximab in data from 161 patients given 375 mg/m2 as an iv infusion for 4 weekly doses.

stor tumorbyrde er defineret som at have mindst et af følgende kriterier:stor tumorbyrde ( 7 cm) , involvering af mindst tre nodale områder (hver 3 cm) , systemiske symptomer (vægttab 10%, feber 38°c i mere end 8 dage, eller natlige svedeture) , splenomegali til under navlen, obstruktion af større organ eller kompressionssyndrom, orbital eller epidural involvering, serøs ekssudation eller leukæmi.
high tumour burden is defined as having at least one of the following: bulky tumour mass ( 7 cm) , involvement of three or more nodal sites (each 3 cm) , systemic symptoms (weight loss 10%, fever 38°c for more than 8 days, or nocturnal sweats) , splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia.